JP2004502638A - 炎症性腸疾患の予防および治療のための生物学的活性ビタミンｄ化合物の使用 - Google Patents

炎症性腸疾患の予防および治療のための生物学的活性ビタミンｄ化合物の使用 Download PDF

Info

Publication number
JP2004502638A
JP2004502638A JP2001547043A JP2001547043A JP2004502638A JP 2004502638 A JP2004502638 A JP 2004502638A JP 2001547043 A JP2001547043 A JP 2001547043A JP 2001547043 A JP2001547043 A JP 2001547043A JP 2004502638 A JP2004502638 A JP 2004502638A
Authority
JP
Japan
Prior art keywords
group
biologically active
compound
vitamin
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001547043A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004502638A5 (enExample
Inventor
ヘイェス　コリーン　イー．
ネイショールド　フェイ　イー．
Original Assignee
ウィスコンシン　アラムニ　リサーチ　ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウィスコンシン　アラムニ　リサーチ　ファンデーション filed Critical ウィスコンシン　アラムニ　リサーチ　ファンデーション
Publication of JP2004502638A publication Critical patent/JP2004502638A/ja
Publication of JP2004502638A5 publication Critical patent/JP2004502638A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
JP2001547043A 1999-12-21 2000-12-21 炎症性腸疾患の予防および治療のための生物学的活性ビタミンｄ化合物の使用 Withdrawn JP2004502638A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/469,985 US6358939B1 (en) 1999-12-21 1999-12-21 Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
PCT/US2000/034913 WO2001046132A1 (en) 1999-12-21 2000-12-21 Use of biologically active vitamin d compounds for the prevention and treatment of inflammatory bowel disease

Publications (2)

Publication Number Publication Date
JP2004502638A true JP2004502638A (ja) 2004-01-29
JP2004502638A5 JP2004502638A5 (enExample) 2008-01-31

Family

ID=23865828

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001547043A Withdrawn JP2004502638A (ja) 1999-12-21 2000-12-21 炎症性腸疾患の予防および治療のための生物学的活性ビタミンｄ化合物の使用

Country Status (9)

Country Link
US (2) US6358939B1 (enExample)
EP (1) EP1240136A4 (enExample)
JP (1) JP2004502638A (enExample)
KR (1) KR100660508B1 (enExample)
AU (1) AU781113B2 (enExample)
CA (1) CA2395200A1 (enExample)
MX (1) MXPA02006257A (enExample)
NO (1) NO326517B1 (enExample)
WO (1) WO2001046132A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
AU4510001A (en) * 1999-12-02 2001-06-18 Penn State Research Foundation, The Treatment of inflammatory bowel disease with vitamin d compounds
US6989377B2 (en) * 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
AU2002902A (en) * 2000-11-14 2002-05-27 Techlab Inc Method for differentiating irritable bowel syndrome from inflammatory bowel disease (ibd) and for monitoring persons with ibd using total endogenous lactoferrinas a marker
US7582670B2 (en) * 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
EP1587906A2 (en) * 2003-01-10 2005-10-26 Eli Lilly And Company Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators
EP1603530A1 (en) * 2003-03-04 2005-12-14 Teva Pharmaceutical Industries Limited Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
GB0307865D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US20050148557A1 (en) * 2003-07-29 2005-07-07 Jin Tian Use of Vitamin Ds to treat kidney disease
US20050192255A1 (en) * 2003-07-30 2005-09-01 Jin Tian Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease
US20050209203A1 (en) * 2003-07-30 2005-09-22 Jin Tian Use of vitamin Ds or vitamin D analogs to treat cardiovascular disease
US20060171983A1 (en) * 2003-07-30 2006-08-03 Jin Tian Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
US7704980B2 (en) * 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
GB0513984D0 (en) * 2005-07-07 2005-08-17 Teva Pharma Dosage form
WO2008103420A1 (en) 2007-02-21 2008-08-28 The Regents Of The University Of Michigan Compositions and methods for tranquilizing heart muscle
CA2681582C (en) * 2007-03-30 2015-07-14 Amgen Inc. Methods of treating bowel disorders
EP2144872A2 (en) * 2007-04-18 2010-01-20 Johns Hopkins University Low calcemic, highly antiproliferative, analogs of calcitriol
US8318708B2 (en) * 2007-11-06 2012-11-27 Salk Institute For Biological Studies Use of vitamin D receptor agonists, ligands, and precursors to treat pancreatic fibrosis
JP2011503104A (ja) 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー 免疫調節化合物ならびに関連組成物および方法
CA2981549A1 (en) 2009-01-27 2010-08-05 Berg Llc Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
AU2010282731C1 (en) 2009-08-14 2016-04-21 Berg Llc Vitamin D3 and analogs thereof for treating alopecia
EP2501705B1 (en) 2009-11-20 2014-08-27 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses
WO2011127302A2 (en) 2010-04-07 2011-10-13 Yue Shen Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
US8618095B2 (en) 2010-04-13 2013-12-31 Rigel Pharmaceuticals, Inc. 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
US20130064859A1 (en) * 2011-01-28 2013-03-14 Sarkis K. Mazmanian Combinatorial vitamin d and probiotic therapy for inflammatory bowel disease
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
PL2723330T3 (pl) * 2011-08-19 2015-12-31 Maria Clementine Martin Klosterfrau Vertriebsges Mbh Lek kombinowany zawierający środek naczynioskurczowy
EP2988752A4 (en) 2013-04-24 2017-01-18 Salk Institute for Biological Studies Vitamin d receptor/smad genomic circuit gates fibrotic response
EP2994161B1 (en) 2013-05-10 2020-10-28 California Institute of Technology Probiotic prevention and treatment of colon cancer
CA2913543C (en) 2013-05-29 2024-01-09 Berg Llc Preventing or mitigating chemotherapy induced alopecia using vitamin d
CN105451818A (zh) 2013-06-05 2016-03-30 萨克生物研究学院 治疗涉及cxcl12活性的疾病的维生素d受体激动剂
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
KR102343093B1 (ko) 2015-02-23 2021-12-24 삼성전자주식회사 식기 세척기 및 그 제어방법
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
CA2997211A1 (en) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Lipidated psa compositions and methods
CA3030974A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
WO2019023149A1 (en) 2017-07-24 2019-01-31 Salk Institute For Biological Studies USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES
JP2025534350A (ja) 2022-09-30 2025-10-15 エクステンド バイオサイエンシズ インコーポレーテッド 長時間作用型副甲状腺ホルモン

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4312806A (en) 1981-03-02 1982-01-26 G. D. Searle & Co. Method and compounds for treating inflammatory bowel disease
US4638043A (en) 1984-11-13 1987-01-20 Thermedics, Inc. Drug release system
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5824313A (en) 1989-09-25 1998-10-20 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5518725A (en) 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5643602A (en) 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
US5216002A (en) 1989-12-21 1993-06-01 Eli Lilly And Company Method of treating inflammatory bowel disease
JP2811353B2 (ja) 1990-07-06 1998-10-15 ゼリア新薬工業株式会社 炎症性腸疾患予防・治療剤
ZA916555B (en) 1990-08-27 1993-04-28 Lilly Co Eli Method of treating inflammatory bowel disease
US5391555A (en) 1991-11-12 1995-02-21 Miles Inc. Methods for treating inflammatory bowel disease with leukotriene synthesis inhibitors
DE4141746A1 (de) 1991-12-13 1993-06-17 Schering Ag 20-methyl-substituierte vitamin d-derivate
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
DK64592D0 (da) 1992-05-14 1992-05-14 Carlbiotech Ltd As Peptider til terapeutisk behandling
DE4221961A1 (de) * 1992-06-30 1994-01-05 Schering Ag 22-En-25-oxa-Derivate in der Vitamin D-Reihe, Verfahren zu ihrer Herstellung, diese Derivate enthaltenen pharmazeutische Präparate sowie deren Verwendung als Arzneimittel
US5294630A (en) 1992-07-07 1994-03-15 Eli Lilly And Company Treatment of inflammatory bowel disease
US5368854A (en) 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
IL107185A (en) * 1992-10-06 1998-02-22 Schering Ag Vitamin d, 25-carboxylic acid derivatives and pharmaceutical compositions containing the same
GB9223061D0 (en) 1992-11-04 1992-12-16 Leo Pharm Prod Ltd Chemical compounds
ATE163262T1 (de) 1993-04-20 1998-03-15 Hexal Ag Wirkstoffplaster
GB9309422D0 (en) 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
GB9314400D0 (en) 1993-07-12 1993-08-25 Leo Pharm Prod Ltd Produktionsaktieselskab) chemical compounds
GB9315253D0 (en) 1993-07-23 1993-09-08 Res Inst Medicine Chem Chemical compounds
US5420109A (en) 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
GB9325415D0 (en) 1993-12-13 1994-02-16 Res Inst Medicine Chem Chemical compounds
DE4405545A1 (de) * 1994-02-22 1995-08-31 Dietl Hans Fettlösliche Vitamine enthaltende Zubereitung zur oralen Applikation
GB9405715D0 (en) 1994-03-23 1994-05-11 Res Inst Medicine Chem Chemical compounds
GB2292079B (en) 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
DK0717034T3 (da) 1994-12-14 1999-10-18 Duphar Int Res Vitamin D-forbindelser og fremgangsmåde til fremstilling af disse forbindelser
PT806413E (pt) 1995-01-23 2002-03-28 Chugai Pharmaceutical Co Ltd Derivados de vitamina d3 substituidos na posicao 2
US5877168A (en) 1995-02-10 1999-03-02 Chugai Seiyaku Kabushiki Kaisha Vitamin D derivative with substituent at the 2β-position
US5569680A (en) 1995-02-13 1996-10-29 Trustees Of The Univ. Of Penna Method of treating inflammatory bowel disease with tributyrin
US5981597A (en) * 1995-02-13 1999-11-09 Trustees Of The University Of Pennsylvania Differentiating agents for the treatment of inflammatory intestinal diseases
GB9509764D0 (en) 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
US5851548A (en) 1995-06-07 1998-12-22 Gen-Probe Incorporated Liposomes containing cationic lipids and vitamin D
UA48973C2 (uk) 1995-06-07 2002-09-16 Орто-Макнейл Фармасьютікалз Інк. Трансдермальний пластир на основі 17-деацетилноргестимату для попередження овуляції
US5711964A (en) 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US5952317A (en) 1995-09-21 1999-09-14 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
ES2144183T3 (es) 1995-10-30 2000-06-01 Hoffmann La Roche 1-alfa,26-dihidroxi-d-homo-vitamina d3.
US5889028A (en) 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5716946A (en) 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
AU710931B2 (en) 1996-02-28 1999-09-30 Sumitomo Pharmaceuticals Company, Limited Crystalline vitamin D derivative
GB9607034D0 (en) 1996-04-03 1996-06-05 Leo Pharm Prod Ltd Chemical compounds
ATE227564T1 (de) 1996-04-04 2002-11-15 Cilag Ag Topische vitamin d zusammensetzung auf liposomenbasis
US5891865A (en) 1996-10-04 1999-04-06 Wisconsin Alumni Research Foundation Treatment of arthritic disease induced by infectious agents
JP2002505668A (ja) * 1997-05-16 2002-02-19 ウィメン アンド インファンツ ホスピタル 環状エーテルビタミンＤ３化合物、１α（ＯＨ）３−エピ−ビタミンＤ３化合物及びそれらの使用法
NL1006072C2 (nl) 1997-05-16 1998-11-17 Jacobs Johannes J Vergister voor het onder aërobe omstandigheden vergisten van dierlijke mest, inrichting en werkwijze voor het onder aërobe omstandigheden vergisten van dierlijke mest onder toepassing van een dergelijke vergister.
US6017908A (en) * 1997-05-16 2000-01-25 Women And Infants Hospital 3-EPI vitamin D2 compounds and uses thereof
US5936105A (en) 1997-06-13 1999-08-10 Tetrionics, Inc. 14-EPI-19-nor-vitamin D compounds and methods
EP0927721A1 (de) * 1997-12-17 1999-07-07 Schering Aktiengesellschaft Neue Vitamin D-Derivate mit Phosphoratomen in den Seitenketten, Zwischenprodukte bei ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
US6214373B1 (en) * 1999-10-07 2001-04-10 Snowden-Sutton Associates, Inc. Nutritional composition for treating inflammatory bowel diseases
US20030188756A1 (en) * 2002-08-19 2003-10-09 Cantorna Margherita T Treatment of inflammatory bowel disease with vitamin d compounds
AU4510001A (en) * 1999-12-02 2001-06-18 Penn State Research Foundation, The Treatment of inflammatory bowel disease with vitamin d compounds
AU7544501A (en) * 2000-09-08 2002-03-22 Wisconsin Alumni Res Found 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications

Also Published As

Publication number Publication date
EP1240136A4 (en) 2004-05-26
US20020128241A1 (en) 2002-09-12
EP1240136A1 (en) 2002-09-18
WO2001046132A1 (en) 2001-06-28
AU2287801A (en) 2001-07-03
KR100660508B1 (ko) 2006-12-22
CA2395200A1 (en) 2001-06-28
NO20022974D0 (no) 2002-06-20
NO326517B1 (no) 2008-12-22
MXPA02006257A (es) 2004-12-06
NO20022974L (no) 2002-08-20
US6858595B2 (en) 2005-02-22
KR20020084075A (ko) 2002-11-04
AU781113B2 (en) 2005-05-05
US6358939B1 (en) 2002-03-19

Similar Documents

Publication Publication Date Title
JP2004502638A (ja) 炎症性腸疾患の予防および治療のための生物学的活性ビタミンｄ化合物の使用
US6989377B2 (en) Treating vitamin D responsive diseases
Couper et al. ISPAD Clinical Practice Consensus Guidelines 2018: Stages of type 1 diabetes in children and adolescents.
Yamamoto et al. Immunological effects of vitamin D and their relations to autoimmunity
Wu et al. The role of vitamin D in immune system and inflammatory bowel disease
Laverny et al. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease
Jiao et al. Butyric acid normalizes hyperglycemia caused by the tacrolimus-induced gut microbiota
Mathieu et al. In vitro and in vivo analysis of the immune system of vitamin D receptor knockout mice
Frisard et al. Toll-like receptor 4 modulates skeletal muscle substrate metabolism
Rios-Arce et al. Epithelial barrier function in gut-bone signaling
Matsumoto et al. Fructo-oligosaccharides and intestinal barrier function in a methionine–choline-deficient mouse model of nonalcoholic steatohepatitis
Oliva-Hemker et al. Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective
Klein et al. Prenatal stress alters immune function in the offspring of rats
Yan et al. Maternal obesity induces sustained inflammation in both fetal and offspring large intestine of sheep
Zhang et al. 1, 25‐dihydroxyvitamin D3 regulates the development of chronic colitis by modulating both T helper (Th) 1 and Th17 activation
Le Bourgot et al. Perinatal short-chain fructooligosaccharides program intestinal microbiota and improve enteroinsular axis function and inflammatory status in high-fat diet-fed adult pigs
US20090209500A1 (en) Use of vitamin d receptor agonists and precursors to treat fibrosis
Stio et al. Interaction among vitamin D3 analogue KH 1060, TNF-α, and vitamin D receptor protein in peripheral blood mononuclear cells of inflammatory bowel disease patients
KR19990066672A (ko) 히스톤을 함유하는 류마티스 관절염 치료제 조성물
CA2370230C (en) Treatment of systemic lupus erythematosis
Gusti et al. Effects of oxandrolone on lean body mass (Lbm) in severe burn patients: a randomized, double blind, placebo-controlled trial
US20040214803A1 (en) Use of vitamin d3 analogue for the treatment of autoimmune diabetes
Hontecillas et al. Expression of PPAR γ in intestinal epithelial cells is dispensable for the prevention of colitis by dietary abscisic acid
Yan et al. Indole-3-carbinol improves survival in lupus-prone mice by inducing tandem B-and T-cell differentiation blockades
EP2015771B1 (en) Modulation of t helper cell-mediated immune responses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071203

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20081216

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090911